The Triple Challenge in Pancreatic Cancer Care
A precision approach for pancreatic cancer
When timing matters most.
The Problem
People diagnosed with advanced pancreatic cancer are quickly confronted with impossible choices. There is no clear path forward, no dependable playbook, and very little time. Treatment decisions—surgery, chemotherapy, radiation, or investigational options—must be made under extreme pressure, often before complete molecular insight is available. Families and clinicians are forced “off road,” navigating high-stakes decisions with incomplete data as the window to act rapidly narrows. Decisions are made under extreme time pressure, often before molecular insight is available.
The Solution
Oncology CoPilot brings AI and genomics enabled decision support into real-world care, helping clinicians act earlier, reduce missed options, and deliver precision medicine when it can still change the course.
The current patient journey
What patients and clinicians face today when confronted with a pancreatic cancer diagnosis.
Pancreatic cancer remains one of the most lethal malignancies, with most patients diagnosed at advanced stage (III/IV) and limited therapeutic options.
Standard first-line treatments, such as FOLFIRINOX or Gemcitabine plus nab-paclitaxel, are aggressive, toxic, and rarely curative. Clinicians must initiate therapy quickly, often within days of diagnosis, knowing that many patients may not tolerate treatment or reach second line.
At the same time, molecular testing is recommended for all patients, yet results frequently return weeks later, after treatment decisions have already been made and started treatment.
Precision medicine exists, but in practice, arrives too late to alter the course of care.
Gaps in real-world care
Despite guideline care, pancreatic cancer faces persistent and compounding gaps.
Delayed Molecular Insight
Germline and somatic NGS results often take 4-6 weeks to return
Actionable findings arrive after therapy has started or the disease has progressed
Reports are static, lengthy, and difficult to interpret for the given time-constraint
Treatment toxicity, patient tolerance, and smaller margins of error
First-line therapies regimens come with significant toxicity concerns
Clinicians are often forced to choose a therapy regimen without full molecular insight
Patient may decline rapidly after therapy has started narrowing potential future options
Limited time and clinical limitations
Rare yet critical biomarkers (e.g. BRCA, MSI-H) are present in only a small fraction of patients
Clinical trials are especially limited due to short timelines cause by the aggressive nature of the disease
It's not a lack of ineligibility, but rather current treatment isn't built to accommodate the speed, synthesis, nor continuous re-assessments needed to improve outcomes
Closing the gap with Oncology CoPilot
Oncology CoPilot is designed to help pancreatic cancer patients and expand clinical knowledge.
We understand the complete tumor biology by using AI to analyze the entire RNA transcriptome to capture active pathways, immune signaling, and functional cancer drivers.
We work for all patients, not just the 10-15% with actionable mutations to deliver clinically relevant insights.
We aim to double treatment-response prediction compared biomarker-based approaches.
With our partners and expedited analysis, we can reduce trial-and-error treatment especially in later stage diagnoses.
We believe in equitable precision medicine and oncology care. Our platform can be leveraged by world-renowned hospitals and community clinics alike to serve vulnerable and underserved patients.
Proven in Practice. Validated in Partnership.
Oncology CoPilot is being developed and validated through rigorous retrospective and prospective studies, in collaboration with leading academic institutions and advocacy partners focused on improving outcomes in pancreatic cancer. Our approach combines real-world clinical deployment with structured validation—ensuring the platform is not only innovative, but clinically meaningful.
Strategic Partnerships
Oncology CoPilot partners with Cellentia to validate AI-driven insights through Lab-in-the-Loop testing of patient-derived organoids and circulating tumor cells, improving confidence in real-world clinical decisions.
Academic Partnerships
Retrospective and prospective validation studies in collaboration with University of California Pancreatic Cancer Consortium, supported through CIAPM, across academic and clinical settings.
Leaders in Precision Medicine
Aligned with Pancreatic Cancer Action Network (PanCAN) initiatives, including Know Your Tumor® and Precision Promise℠, to expand retrospective validation.
Leading Cancer Centers
Launching Clinical collaboration with Moffitt Cancer Center, supporting validation in pancreatic cancer programs.
Expanding Nationally
Scaling validation through MD Anderson Cancer Center, enabled by Cancer Prevention and Research Institute of Texas (CPRIT) support.
Real-world Impact
Earlier identification of actionable alterations, improved trial surfacing, and reduced delays between molecular insight and clinical decisions.